Butow Phyllis, Sharpe Louise, Thewes Belinda, Turner Jane, Gilchrist Jemma, Beith Jane
Oncology (Williston Park). 2018 Jan 15;32(1):32-8.
With increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients' quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status. Oncologists can assess and screen for FCR using validated measures; provide adequate information about prognosis, signs and symptoms of recurrence, and behavioral strategies for risk reduction and follow-up; and warn patients and families that FCR may be an issue in survivorship. It is important to normalize FCR and encourage patients to discuss it if it is a concern. Patients with severe FCR should be referred to psycho-oncology staff, who can apply some of the novel psychotherapeutic interventions that have emerged to address this condition.
随着癌症生存率的提高，对癌症复发的恐惧（FCR）正成为一个突出的临床问题。FCR普遍存在、令人痛苦且持续时间长，会对患者的生活质量、医疗服务利用以及对随访建议的依从性产生负面影响。新型靶向治疗可能会增加FCR的风险，原因在于治疗持续时间和随访时间延长、预后精准度提高以及基于基因组状态的治疗省略。肿瘤学家可以使用经过验证的措施评估和筛查FCR；提供有关预后、复发体征和症状以及降低风险和随访的行为策略的充分信息；并警告患者及其家属FCR可能是生存期间的一个问题。将FCR正常化并鼓励患者在担忧时进行讨论很重要。严重FCR的患者应转诊至心理肿瘤学工作人员处，他们可以应用一些新出现的针对这种情况的心理治疗干预措施。
